Eli Lilly and Co (LLY)
750.77
+4.03
(+0.54%)
USD |
NYSE |
Apr 17, 16:00
753.60
+2.83
(+0.38%)
Pre-Market: 04:46
Eli Lilly Free Cash Flow: -3.152B for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
Date | Value |
---|---|
December 31, 2023 | -3.152B |
September 30, 2023 | -164.90M |
June 30, 2023 | 3.211B |
March 31, 2023 | 3.786B |
December 31, 2022 | 4.600B |
September 30, 2022 | 5.339B |
June 30, 2022 | 4.950B |
March 31, 2022 | 5.824B |
December 31, 2021 | 5.388B |
September 30, 2021 | 4.621B |
June 30, 2021 | 4.837B |
March 31, 2021 | 5.565B |
December 31, 2020 | 4.470B |
September 30, 2020 | 5.112B |
June 30, 2020 | 4.890B |
March 31, 2020 | 3.684B |
December 31, 2019 | 3.483B |
September 30, 2019 | 2.671B |
June 30, 2019 | 3.324B |
March 31, 2019 | 2.217B |
December 31, 2018 | 2.506B |
September 30, 2018 | 2.931B |
June 30, 2018 | 2.543B |
March 31, 2018 | 4.313B |
December 31, 2017 | 3.452B |
Date | Value |
---|---|
September 30, 2017 | 3.744B |
June 30, 2017 | 3.744B |
March 31, 2017 | 3.472B |
December 31, 2016 | 3.759B |
September 30, 2016 | 2.659B |
June 30, 2016 | 2.006B |
March 31, 2016 | 1.438B |
December 31, 2015 | 1.338B |
September 30, 2015 | 1.570B |
June 30, 2015 | 2.138B |
March 31, 2015 | 2.349B |
December 31, 2014 | 2.892B |
September 30, 2014 | 3.400B |
June 30, 2014 | 3.789B |
March 31, 2014 | 4.490B |
December 31, 2013 | 4.642B |
September 30, 2013 | 4.612B |
June 30, 2013 | 4.202B |
March 31, 2013 | 3.794B |
December 31, 2012 | 4.261B |
September 30, 2012 | 4.770B |
June 30, 2012 | 5.167B |
March 31, 2012 | 5.573B |
December 31, 2011 | 5.542B |
September 30, 2011 | 5.834B |
Free Cash Flow Range, Past 5 Years
-3.152B
Minimum
Dec 2023
5.824B
Maximum
Mar 2022
3.812B
Average
4.600B
Median
Dec 2022
Free Cash Flow Benchmarks
Amgen Inc | 7.359B |
Madrigal Pharmaceuticals Inc | -325.71M |
Vertex Pharmaceuticals Inc | 3.279B |
Viking Therapeutics Inc | -73.38M |
Moderna Inc | -3.825B |
Free Cash Flow Related Metrics
Cash from Operations (Quarterly) | -311.90M |
Cash from Investing (Quarterly) | -2.924B |
Cash from Financing (Quarterly) | 3.545B |
Free Cash Flow Per Share (Quarterly) | -2.172 |
Free Cash Flow to Equity (Quarterly) | -7.02B |
Free Cash Flow to Firm (Quarterly) | -1.881B |
Free Cash Flow Yield | -0.47% |